Referencia número: HY-14398

Celecoxib

(Synonyms: SC 58635)

64 Cited Publications

Revisión del cliente

Based on 64 publication(s) in Google Scholar

Celecoxib,a selective and BBB-permeable non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC₅₀ of 40 nM.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.97%
No. CAS: 169590-42-5
Fòrmula: C₁₇H₁₄F₃N₃O₂S
Peso molecular:381.37

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Celecoxib Chemical Structure

No. CAS: 169590-42-5

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (64)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Celecoxib,a selective and BBB-permeable non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC₅₀ of 40 nM.

IC₅₀ & Target^[1]

COX-2

40 nM (IC₅₀)

COX-1

15 μM (IC₅₀)

Ver todos los productos específicos de isoformas COX :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	18.1 μM Compound: Cel	Cytotoxicity against human A2780 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay	[PMID: 37567059]
A549	IC₅₀	15.6 μM Compound: Celecoxib	Antitumor activity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 23353741]
A549	IC₅₀	2.15 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
A549	IC₅₀	15.64 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	[PMID: 27349331]
A549	IC₅₀	7.68 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28720504]
A549	IC₅₀	16.08 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30031652]
A549	IC₅₀	11.04 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
A549	IC₅₀	17.5 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32485532]
A549	IC₅₀	16.3 μM Compound: Celecoxib	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation	[PMID: 34217828]
A549	IC₅₀	57.87 μM Compound: Celecoxib	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
B16-F10	IC₅₀	85.6 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT colorimetric assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT colorimetric assay	[PMID: 22000948]
B16-F10	IC₅₀	85.9 μM Compound: Celecoxib	Antitumor activity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 23353741]
B16-F10	IC₅₀	4.56 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 25866240]
B16-F10	IC₅₀	14.36 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 27349331]
B16-F10	IC₅₀	19.15 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 30031652]
B16-F10	IC₅₀	13.27 μM Compound: Celecoxib	Antiproliferative activity against mouse B16F10 cells incubated for 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
B16-F10	IC₅₀	16.2 μM Compound: Celecoxib	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell proliferation Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell proliferation	[PMID: 34217828]
C6	IC₅₀	>40 μM Compound: Celecoxib	Antiproliferative activity against rat C6 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay Antiproliferative activity against rat C6 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 34091208]
Caco-2	IC₅₀	42.74 μM Compound: Celecoxib	Antiproliferative activity against human Caco2 cells by MTT assay Antiproliferative activity against human Caco2 cells by MTT assay	[PMID: 30216848]
CHO	IC₅₀	0.002 μM Compound: 2, SC-58635	In vitro potency against human Prostaglandin G/H synthase 2 in transfected CHO cells. In vitro potency against human Prostaglandin G/H synthase 2 in transfected CHO cells.	[PMID: 10197970]
CHO	IC₅₀	0.002 μM Compound: Celecoxib	In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells	[PMID: 10576684]
CHO	IC₅₀	0.002 μM Compound: Celecoxib	Inhibition of PGE-2 production in CHO cells expressing human COX-2. Inhibition of PGE-2 production in CHO cells expressing human COX-2.	[PMID: 10576685]
CHO	IC₅₀	0.002 μM Compound: Celecoxib	Inhibitory of human Prostaglandin G/H synthase 2 expressed in CHO cells. Inhibitory of human Prostaglandin G/H synthase 2 expressed in CHO cells.	[PMID: 12643942]
CHO	IC₅₀	0.036 μM Compound: celecoxib	Inhibition of COX2 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay Inhibition of COX2 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay	[PMID: 15566290]
CHO	IC₅₀	13.5 μM Compound: celecoxib	Inhibition of COX1 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay Inhibition of COX1 expressed in CHO cells assessed as inhibition of arachidonic acid-stimulated PGE2 production by enzyme immunoassay	[PMID: 15566290]
DU-145	IC₅₀	59.34 μM Compound: Celecoxib	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
HCT-116	IC₅₀	43.3 μM Compound: Celecoxib	Anticancer activity against human HCT116 cells after 72 hrs by MTT assay Anticancer activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 21678971]
HCT-116	IC₅₀	29.54 μM Compound: Celecoxib	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	[PMID: 30216848]
HEK-293T	CC₅₀	72.42 μM Compound: Celecoxib	Cytotoxicity against human 293T cells after 24 hrs by MTT assay Cytotoxicity against human 293T cells after 24 hrs by MTT assay	[PMID: 25866240]
HEK-293T	CC₅₀	54.38 μM Compound: Celecoxib	Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
HEK-293T	IC₅₀	95.26 μM Compound: Celecoxib	Antiproliferative activity against human 293T cells after 24 hrs by MTT assay Antiproliferative activity against human 293T cells after 24 hrs by MTT assay	[PMID: 27349331]
HEK-293T	IC₅₀	111.86 μM Compound: Celecoxib	Antiproliferative activity against human 293T cells after 48 hrs by MTT assay Antiproliferative activity against human 293T cells after 48 hrs by MTT assay	[PMID: 28720504]
HEK-293T	IC₅₀	224.86 μM Compound: Celecoxib	Cytotoxicity against human 293T cells after 48 hrs by MTT assay Cytotoxicity against human 293T cells after 48 hrs by MTT assay	[PMID: 30031652]
HEK-293T	CC₅₀	55.83 μM Compound: Celecoxib	Cytotoxicity against human 293T cells by MTT assay Cytotoxicity against human 293T cells by MTT assay	[PMID: 30342958]
HEK-293T	CC₅₀	55.83 μmol Compound: Celecoxib	Cytotoxicity against human 293T cells by MTT assay Cytotoxicity against human 293T cells by MTT assay	[PMID: 30342958]
HEK-293T	IC₅₀	97.87 μM Compound: Celecoxib	Antiproliferative activity against human 293T cells incubated for 48 hrs by MTT assay Antiproliferative activity against human 293T cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
HeLa	IC₅₀	7.35 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 25866240]
HeLa	IC₅₀	7.55 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
HeLa	IC₅₀	7.79 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 27349331]
HeLa	IC₅₀	11.06 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28720504]
HeLa	IC₅₀	15.69 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30031652]
HeLa	IC₅₀	36.08 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 30216848]
HeLa	IC₅₀	7.55 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30342958]
HeLa	IC₅₀	15.68 μM Compound: Celecoxib	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
HeLa	IC₅₀	58.2 μM Compound: Celecoxib	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
HeLa	IC₅₀	32.7 μM Compound: CXB	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation	[PMID: 36634752]
HepG2	IC₅₀	95.5 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT colorimetric assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT colorimetric assay	[PMID: 22000948]
HepG2	IC₅₀	0.76 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
HepG2	IC₅₀	10.03 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 27349331]
HepG2	IC₅₀	0.78 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30342958]
HepG2	IC₅₀	0.36 μM Compound: Celecoxib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32485532]
HepG2	IC₅₀	58.2 μM Compound: Celecoxib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
HepG2	IC₅₀	43.6 μM Compound: CXB	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation	[PMID: 36634752]
HL-60	IC₅₀	44.72 μM Compound: Celecoxib	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
HT-29	IC₅₀	45.5 μM Compound: celecoxib	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 20804197]
HT-29	IC₅₀	18 μg/mL Compound: Celecoxib	Antiproliferative activity against human HT-29 cells after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 22750009]
HT-29	IC₅₀	18.3 μM Compound: Celecoxib	Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in human HT-29 cells expressing Has2 assessed as decrease in cell survival after 18 hrs by MTS assay Inhibition of hyaluronan-induced CD44 antigen variant exon 6 activity in human HT-29 cells expressing Has2 assessed as decrease in cell survival after 18 hrs by MTS assay	[PMID: 23517721]
HT-29	IC₅₀	3 μM Compound: Celecoxib	Cytotoxicity against human HT-29 cells assessed as decrease in cell survival after 18 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as decrease in cell survival after 18 hrs by MTS assay	[PMID: 23517721]
HT-29	IC₅₀	0.7 μM Compound: Celecoxib	Cytotoxicity against COX-2 positive human HT-29 cells transfected with CD44v6shRNA assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against COX-2 positive human HT-29 cells transfected with CD44v6shRNA assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24295787]
HT-29	IC₅₀	5.7 μM Compound: Celecoxib	Cytotoxicity against COX-2 positive human HT-29 cells assessed as growth inhibition by CellTiter-96 AQueous assay Cytotoxicity against COX-2 positive human HT-29 cells assessed as growth inhibition by CellTiter-96 AQueous assay	[PMID: 24295787]
HT-29	IC₅₀	8.47 μM Compound: Celecoxib	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 28720504]
HT-29	IC₅₀	17.97 μM Compound: Celecoxib	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33477020]
HT-29	IC₅₀	32.5 μM Compound: Cel	Cytotoxicity against human HT-29 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay	[PMID: 37567059]
J774	IC₅₀	0.079 μM Compound: Celecoxib	In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells	[PMID: 15857149]
J774	IC₅₀	5.1 μM Compound: Celecoxib	In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells	[PMID: 15857149]
J774	IC₅₀	0.06 μM Compound: celecoxib	Inhibition of COX2 in LPS-stimulated J774 cells assessed as inhibition of PGE2 levels by radioimmunoassay Inhibition of COX2 in LPS-stimulated J774 cells assessed as inhibition of PGE2 levels by radioimmunoassay	[PMID: 17915854]
J774	IC₅₀	3.7 μM Compound: celecoxib	Inhibition of COX1 in mouse J774 cells assessed as arachidonic acid-induced PGE2 levels by radio immunoassay Inhibition of COX1 in mouse J774 cells assessed as arachidonic acid-induced PGE2 levels by radio immunoassay	[PMID: 17915854]
J774	IC₅₀	0.06 μM Compound: 1b	Inhibition of COX2 in LPS-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay Inhibition of COX2 in LPS-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay	[PMID: 18752957]
J774	IC₅₀	3.7 μM Compound: 1b	Inhibition of COX1 in arachidonic acid-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay Inhibition of COX1 in arachidonic acid-stimulated mouse J774 cells assessed as inhibition of PGE2 production after 15 mins by radioimmunoassay	[PMID: 18752957]
J774	IC₅₀	0.079 μM Compound: 1b	Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA	[PMID: 19957931]
J774	IC₅₀	5.1 μM Compound: 1b	Inhibition of COX1-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA Inhibition of COX1-dependent PGE2 production in LPS-stimulated mouse J774 cells by RIA	[PMID: 19957931]
J774	IC₅₀	80 μM Compound: 1b	Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 1 uM by RIA Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 1 uM by RIA	[PMID: 19957931]
J774	IC₅₀	95 μM Compound: 1b	Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 10 uM by RIA Inhibition of COX2-dependent PGE2 production in LPS-stimulated mouse J774 cells at 10 uM by RIA	[PMID: 19957931]
J774	IC₅₀	0.061 μM Compound: Celecoxib	Inhibition of COX-2-mediated PGE2 production in LPS-stimulated mouse J774 cells after 24 hrs by radioimmunoassay Inhibition of COX-2-mediated PGE2 production in LPS-stimulated mouse J774 cells after 24 hrs by radioimmunoassay	[PMID: 21992176]
J774	IC₅₀	3.84 μM Compound: Celecoxib	Inhibition of COX-1-mediated PGE2 production in arachidonic acid-stimulated mouse J774 cells incubated for 15 mins prior to arachidonic acid-challenge by radioimmunoassay Inhibition of COX-1-mediated PGE2 production in arachidonic acid-stimulated mouse J774 cells incubated for 15 mins prior to arachidonic acid-challenge by radioimmunoassay	[PMID: 21992176]
J774	IC₅₀	0.061 μM Compound: Celecoxib	Inhibition of COX2 in mouse J774 cells assessed as inhibition of LPS-induced PGE2 production by radioimmunoassay Inhibition of COX2 in mouse J774 cells assessed as inhibition of LPS-induced PGE2 production by radioimmunoassay	[PMID: 23680444]
J774	IC₅₀	3.84 μM Compound: Celecoxib	Inhibition of COX1 in mouse J774 cells using arachidonic acid as substrate assessed as inhibition of PGE2 production incubated for 15 mins prior to substrate addition measured after 30 mins by radioimmunoassay Inhibition of COX1 in mouse J774 cells using arachidonic acid as substrate assessed as inhibition of PGE2 production incubated for 15 mins prior to substrate addition measured after 30 mins by radioimmunoassay	[PMID: 23680444]
Jurkat	IC₅₀	32.13 μM Compound: Celecoxib	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
K562	IC₅₀	57.81 μM Compound: Celecoxib	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
L02	IC₅₀	98.15 μM Compound: Celecoxib	Antiproliferative activity against human LO2 cells after 24 hrs by MTT assay Antiproliferative activity against human LO2 cells after 24 hrs by MTT assay	[PMID: 27349331]
L02	CC₅₀	78.2 μM Compound: Celecoxib	Cytotoxicity against human LO2 cells by MTT assay Cytotoxicity against human LO2 cells by MTT assay	[PMID: 30342958]
L02	CC₅₀	78.2 μmol Compound: Celecoxib	Cytotoxicity against human LO2 cells by MTT assay Cytotoxicity against human LO2 cells by MTT assay	[PMID: 30342958]
L1210	IC₅₀	44 μM Compound: Celecoxib	Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay	[PMID: 20451397]
LNCaP	IC₅₀	50.4 μM Compound: celecoxib	Antiproliferative activity against androgen-sensitive human LNCaP cells after 72 hrs by MTT test Antiproliferative activity against androgen-sensitive human LNCaP cells after 72 hrs by MTT test	[PMID: 15566290]
LNCaP	IC₅₀	32.6 μM Compound: Celecoxib	Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
LNCaP	IC₅₀	16.4 μM Compound: Celecoxib	Cytotoxicity against human LNCaP cells over expressing androgen receptor F876L mutant assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human LNCaP cells over expressing androgen receptor F876L mutant assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
MC9	IC₅₀	0.3 μM Compound: celecoxib	Inhibition of PGF2apha production in arachidonic acid-stimulated mouse MC9 cells Inhibition of PGF2apha production in arachidonic acid-stimulated mouse MC9 cells	[PMID: 18498150]
MC9	IC₅₀	0.4 μM Compound: celecoxib	Inhibition of PGF2alpha production in mouse MC9 cells Inhibition of PGF2alpha production in mouse MC9 cells	[PMID: 18498150]
MCF7	IC₅₀	50.2 μM Compound: Celecoxib	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20451397]
MCF7	IC₅₀	40.8 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT colorimetric assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT colorimetric assay	[PMID: 22000948]
MCF7	IC₅₀	40.8 μM Compound: Celecoxib	Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 23353741]
MCF7	IC₅₀	5.94 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 25866240]
MCF7	IC₅₀	6.88 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
MCF7	IC₅₀	49.66 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29191502]
MCF7	IC₅₀	26.78 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30031652]
MCF7	IC₅₀	31.28 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 30216848]
MCF7	IC₅₀	6.96 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30342958]
MCF7	IC₅₀	12.57 μM Compound: Celecoxib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 30877972]
MCF7	IC₅₀	2.56 μM Compound: Celecoxib	Antiproliferative activity against human MCF-7 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay Antiproliferative activity against human MCF-7 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay	[PMID: 32485532]
MCF7	IC₅₀	15.98 μM Compound: Celecoxib	Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33477020]
MCF7	IC₅₀	19.78 μM Compound: Celecoxib	Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33477020]
MCF7	IC₅₀	64.19 μM Compound: Celecoxib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
MCF7	IC₅₀	15.4 μM Compound: Cel	Cytotoxicity against human MCF7 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition in cell growth incubated for 72 hrs by MTT assay	[PMID: 37567059]
MDA-MB-231	IC₅₀	40 μM Compound: CCB	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS assay	[PMID: 22780961]
MDA-MB-231	IC₅₀	22.79 μM Compound: Celecoxib	Antiproliferative activity against human MDA231 cells by MTT assay Antiproliferative activity against human MDA231 cells by MTT assay	[PMID: 30216848]
MDA-MB-231	IC₅₀	69.64 μM Compound: Celecoxib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
NALM-6	IC₅₀	28.58 μM Compound: Celecoxib	Antiproliferative activity against human NALM-6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NALM-6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36395680]
PC-3	IC₅₀	47 μM Compound: celecoxib	Antiproliferative activity against androgen-independent human PC3 cells after 72 hrs by MTT test Antiproliferative activity against androgen-independent human PC3 cells after 72 hrs by MTT test	[PMID: 15566290]
PC-3	IC₅₀	48 μM Compound: Celecoxib	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 17937972]
PC-3	GI₅₀	4.7 x 10^-5 M Compound: Celecoxib	Anticancer activity against human PC3 cells Anticancer activity against human PC3 cells	[PMID: 18262309]
PC-3	IC₅₀	48.5 μM Compound: Celecoxib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20451397]
PC-3	IC₅₀	48 μM Compound: 1	Inhibition of PDK1-mediated Akt activation in human PC3 cells after 2 hrs by Western blotting analysis Inhibition of PDK1-mediated Akt activation in human PC3 cells after 2 hrs by Western blotting analysis	[PMID: 23735281]
RAW264.7	IC₅₀	17 μg/mL Compound: Celecoxib	Cytotoxicity against mouse RAW264.7 cells after 8 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 8 hrs by MTT assay	[PMID: 19398640]
RAW264.7	IC₅₀	0.1 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production	[PMID: 22000948]
RAW264.7	IC₅₀	11130 μM Compound: Celecoxib	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability by propidium iodide staining based FACS-flow cytometry Cytotoxicity against mouse RAW264.7 cells assessed as cell viability by propidium iodide staining based FACS-flow cytometry	[PMID: 22494844]
RAW264.7	IC₅₀	12090 μM Compound: Celecoxib	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 22494844]
RAW264.7	IC₅₀	0.12 μM Compound: Celecoxib	Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production	[PMID: 23353741]
RAW264.7	IC₅₀	0.0087 μM Compound: Celecoxib, Celebrex	Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay	[PMID: 24656662]
RAW264.7	IC₅₀	1.28 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA	[PMID: 24679441]
RAW264.7	IC₅₀	1.84 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis	[PMID: 24679441]
RAW264.7	IC₅₀	1.6 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay	[PMID: 26444098]
RAW264.7	IC₅₀	34.3 μM Compound: Celecoxib	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of cell growth Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of cell growth	[PMID: 33454546]
RAW264.7	IC₅₀	10.69 μM Compound: Celecoxib	Inhibition of LPS-induced TNFalpha production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Inhibition of LPS-induced TNFalpha production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 33892270]
RAW264.7	IC₅₀	11.17 μM Compound: Celecoxib	Inhibition of LPS-induced IL-6 production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Inhibition of LPS-induced IL-6 production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 33892270]
RAW264.7	IC₅₀	11.73 μM Compound: Celecoxib	Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced intracellular ROS production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA staining based fluorescence analysis Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced intracellular ROS production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA staining based fluorescence analysis	[PMID: 33892270]
RAW264.7	IC₅₀	19.58 μM Compound: Celecoxib	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by DAF-FM based fluorescence analysis Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by DAF-FM based fluorescence analysis	[PMID: 33892270]
RAW264.7	IC₅₀	7.46 μM Compound: Celecoxib	Inhibition of LPS-induced 15(S)-HETE production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Inhibition of LPS-induced 15(S)-HETE production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 33892270]
RAW264.7	IC₅₀	2.3 μM Compound: Celecoxib	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated with compound for 2 hrs followed by LPS stimulation measured after 18 hrs by gGriess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated with compound for 2 hrs followed by LPS stimulation measured after 18 hrs by gGriess reagent based assay	[PMID: 34658231]
RAW264.7	IC₅₀	23.09 μM Compound: Celecoxib	Anti inflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated with LPS for 4 hrs followed by compound addition and measured after 18 hrs by griess reagent based assay Anti inflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated with LPS for 4 hrs followed by compound addition and measured after 18 hrs by griess reagent based assay	[PMID: 37146344]
RAW264.7	IC₅₀	16.52 μM Compound: Celecoxib	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of ROS production by DCFH-DA staining based assay Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of ROS production by DCFH-DA staining based assay	[PMID: 37182334]
RAW264.7	IC₅₀	22.89 μM Compound: Celecoxib	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by DAF-FM staining based assay Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by DAF-FM staining based assay	[PMID: 37182334]
RAW264.7	IC₅₀	3.12 μM Compound: Celecoxib	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of IL-6 production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of IL-6 production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method	[PMID: 37182334]
RAW264.7	IC₅₀	4.14 μM Compound: Celecoxib	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method	[PMID: 37182334]
RAW264.7	IC₅₀	16.5 μM Compound: Celecoxib	Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis	[PMID: 37224762]
RAW264.7	IC₅₀	12.2 μM Compound: Celecoxib	Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	13.7 μM Compound: Celecoxib	Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	14.6 μM Compound: Celecoxib	Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	17.89 μM Compound: Celecoxib	Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs in presence of LPS by griess reagent based assay Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs in presence of LPS by griess reagent based assay	[PMID: 37561816]
RAW264.7	IC₅₀	17.94 μM Compound: Celecoxib	Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA Inhibition of IL-1beta production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	21.1 μM Compound: Celecoxib	Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by griess reagent based assay Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by griess reagent based assay	[PMID: 37561816]
RAW264.7	IC₅₀	36.04 μM Compound: Celecoxib	Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA Inhibition of IL-6 production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	41.18 μM Compound: Celecoxib	Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA Inhibition of TNF-alpha production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by ELISA	[PMID: 37561816]
RAW264.7	IC₅₀	3.12 μM Compound: Cpd I	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 37611534]
RAW264.7	IC₅₀	4.36 μM Compound: Cpd I	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 37611534]
RAW264.7	IC₅₀	49.37 μM Compound: Cpd I	Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced ROS production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA probe based fluorescence analysis Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced ROS production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA probe based fluorescence analysis	[PMID: 37611534]
RAW264.7	IC₅₀	50.9 μM Compound: Cpd I	Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by fluorescence microscopic analysis Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by fluorescence microscopic analysis	[PMID: 37611534]
Sf9	IC₅₀	0.036 μM Compound: celecoxib	Inhibitory activity against human Prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus Inhibitory activity against human Prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus	[PMID: 14698190]
Sf9	IC₅₀	0.036 μM Compound: Celecoxib	In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus	[PMID: 15026050]
Sf9	IC₅₀	>100 μM Compound: celecoxib	Inhibition of human COX1 expressed in sf9 cells Inhibition of human COX1 expressed in sf9 cells	[PMID: 16252917]
Sf9	IC₅₀	0.08 μM Compound: celecoxib	Inhibition of human COX2 expressed in sf9 cells Inhibition of human COX2 expressed in sf9 cells	[PMID: 16252917]
Sf9	IC₅₀	63 nM Compound: 3	Inhibition of human COX2 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay Inhibition of human COX2 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay	[PMID: 19520573]
Sf9	IC₅₀	>1000 nM Compound: 3	Inhibition of human COX1 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay Inhibition of human COX1 expressed in baculovirus-infected SF9 cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay	[PMID: 19520573]
Sf9	IC₅₀	0.04 μM Compound: 2	Inhibition of recombinant human COX-2 expressed in Baculovirus infected sf9 cells using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by ELISA Inhibition of recombinant human COX-2 expressed in Baculovirus infected sf9 cells using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by ELISA	[PMID: 30396033]
SH-SY5Y	IC₅₀	5 μM Compound: Celecoxib	Antineurotoxicity in human SH-SY5Y cells assessed as inhibition human THP1 cell supernatant-induced cytotoxicity compound pretreated 24 to 48 hrs to THP1 cells measured after 72 hrs of supernatant addition Antineurotoxicity in human SH-SY5Y cells assessed as inhibition human THP1 cell supernatant-induced cytotoxicity compound pretreated 24 to 48 hrs to THP1 cells measured after 72 hrs of supernatant addition	[PMID: 20138770]
SMMC-7721	IC₅₀	5.96 μM Compound: Celecoxib	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 28720504]
SW480	IC₅₀	6.9 μM Compound: Celecoxib	Cytotoxicity against COX-2 negative human SW480 cells assessed as growth inhibition by CellTiter-96 AQueous assay Cytotoxicity against COX-2 negative human SW480 cells assessed as growth inhibition by CellTiter-96 AQueous assay	[PMID: 24295787]
THP-1	EC₅₀	50 μM Compound: Celecoxib	Cytotoxicity against LPS and IFN-gamma-stimulated human THP1 cells after 24 hrs Cytotoxicity against LPS and IFN-gamma-stimulated human THP1 cells after 24 hrs	[PMID: 20138770]
THP-1	EC₅₀	50 μM Compound: Celecoxib	Cytotoxicity against human THP1 cells assessed as reduction in cell viability Cytotoxicity against human THP1 cells assessed as reduction in cell viability	[PMID: 20609589]
THP-1	IC₅₀	5 μM Compound: Celecoxib	Neuroprotective activity against LPS and IFN-gamma-stimulated neurotoxin production in human THP1 cell assessed as inhibition of THP1 cell secretion-induced toxicity to human SH-SY5Y cells after 72 hrs by MTT assay Neuroprotective activity against LPS and IFN-gamma-stimulated neurotoxin production in human THP1 cell assessed as inhibition of THP1 cell secretion-induced toxicity to human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 20609589]
THP-1	IC₅₀	70 μM Compound: Celecoxib	Antiinflammatory activity in human THP1 cells assessed as reduction in LPS and IFN-gamma-induced MCP level after 24 hrs Antiinflammatory activity in human THP1 cells assessed as reduction in LPS and IFN-gamma-induced MCP level after 24 hrs	[PMID: 20609589]
U-251	IC₅₀	>40 μM Compound: Celecoxib	Antiproliferative activity against human U-251 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 34091208]
U-87MG ATCC	IC₅₀	>40 μM Compound: Celecoxib	Antiproliferative activity against human U-87 MG cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human U-87 MG cells assessed as growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 34091208]
U-937	IC₅₀	0.05 μM Compound: Celecoxib	Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes. Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes.	[PMID: 10576685]
U-937	IC₅₀	5.1 μM Compound: 2	Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma	[PMID: 11462976]
U-937	IC₅₀	5.1 μM Compound: 2 (celecoxib)	In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells	[PMID: 12877584]
UACC-903	IC₅₀	55.6 μM Compound: Celecoxib	Anticancer activity against human UACC-903 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay Anticancer activity against human UACC-903 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay	[PMID: 34217061]
Vero	IC₅₀	60.63 μM Compound: Celecoxib	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 35134642]
WI-38	IC₅₀	432.9 μM Compound: Celecoxib	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32485532]
WM-115	IC₅₀	55.6 μM Compound: Celecoxib	Anticancer activity against human WM-115 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay Anticancer activity against human WM-115 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay	[PMID: 34217061]

In Vitro

The selective cyclooxygenase-2 (COX-2) inhibitor Celecoxib (10-75 μM) inhibits the proliferation of the NPC cell lines in a dose-dependent manner. Celecoxib (25 and 50 μM) induces apoptosis and cell-cycle arrest at the G₀/G₁ checkpoint in the NPC cell lines, which is associated with significantly reduced STAT3 phosphorylation. The genes downstream of STAT3 (ie, Survivin, Mcl-1, Bcl-2 and Cyclin D1) are significantly down-regulated after exposure to Celecoxib (25 and 50 μM)^[2].
Targeting the YAP/TAZ transcriptional target cyclooxygenase 2 (COX-2) using celecoxib inhibits cell proliferation and tumorigenesis in NF2 mutant cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Celecoxib demonstrates potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay with an ED₅₀ of 7.1 mg/kg and reduces chronic inflammation in the adjuvant arthritis model with an ED₅₀ of 0.37 mg/kg/day. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with an ED₅₀ of 34.5 mg/kg. Celecoxib has potency equivalent to that of standard nonsteroidal anti-inflammatory drugs (NSAIDs), yet shows no acute GI toxicity in rats at doses up to 200 mg/kg. In addition, it displays no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days^[1]. In the KpB mice fed a high fat diet (obese) and treated with Celecoxib, tumor weight decreases by 66% when compare with control animals. Among KpB mice fed a low fat diet (non-obese), tumor weight decreases by 46% after treatment with Celecoxib^[3]. Rat models are orally administrated with Celecoxib (20 mg/kg) and/or intramuscularly with Fasudil (10 mg/kg) for 2 weeks. Results demonstrates that the combined use of Celecoxib and fasudil significantly decreases COX-2 and Rho kinase II expression surrounding the lesion site in rats with spinal cord injury, improves the pathomorphology of the injured spinal cord, and promoted the recovery of motor function^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 169590-42-5
Appearance Solid
Peso molecular 381.37
Fòrmula C₁₇H₁₄F₃N₃O₂S
Color White to off-white
SMILES

CC1=CC=C(C=C1)C2=CC(C(F)(F)F)=NN2C3=CC=C(C=C3)S(=O)(N)=O
Synonyms

SC 58635
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (64)

All WB

Sort by:

Journal Impact Factor

Science

Direct sensing of dietary ω-6 linoleic acid through FABP5-mTORC1 signaling. [Abstract]

2025 Mar 14;387(6739):eadm9805. PMID: 40080571
Cancer Discov

Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T cells in KRAS-Mutant Cholangiocarcinoma. [Abstract]

2026 Apr 8. PMID: 41949259
Nat Biomed Eng

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. [Abstract]

2018 Aug;2(8):578-588. PMID: 31015631
Adv Funct Mater

2025 Apr 21.
Cancer Res

ACSL5 Mediates Adaptation to the Palmitic Acid-Enriched Pulmonary Microenvironment to Enhance Metastatic Breast Cancer Cell Survival and Lung Metastasis. [Abstract]

2026 Jan 22. PMID: 41570334
ACS Nano

Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer. [Abstract]

2024 Jun 18;18(24):15864-15877. PMID: 38829727
Hepatology

Eosinophils protect against acetaminophen-induced liver injury through cyclooxygenase-mediated IL-4/IL-13 production. [Abstract]

2023 Feb 1;77(2):456-465. PMID: 35714036
J Clin Invest

Dietary omega-6 lipids promote post-injury aberrant bone formation in obesity. [Abstract]

2026 Jun 11:e205829. PMID: 42275145
Theranostics

KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8+ T-cell-dependent antitumor immunity. [Abstract]

2023 Feb 21; 13(4): 1381-1400. PMID: 36923542
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
J Exp Clin Cancer Res

3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE2 pathway. [Abstract]

2020 Jun 16;39(1):113. PMID: 32546278
Small

Self-Assembled Carrier-Free Nanomedicines Potentiate Chemo-Photothermal Immunotherapy by Overcoming Prostaglandin E2-Mediated Immunosuppression. [Abstract]

2026 Apr;22(20):e12540. PMID: 41665479
J Biomed Sci

Exosomal PGE2 from M2 macrophages inhibits neutrophil recruitment and NET formation through lipid mediator class switching in sepsis. [Abstract]

2023 Aug 2;30(1):62. PMID: 37533081
J Control Release

Co-delivery of a STING agonist and indoleamine 2,3-dioxygenase 1 blockade activates type I dendritic cells in cancer. [Abstract]

2026 Apr 10:392:114731. PMID: 41702511
Dev Cell

A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. [Abstract]

2025 Sep 3:S1534-5807(25)00530-1. PMID: 40930100
Acta Pharmacol Sin

6-O-angeloylplenolin exerts neuroprotection against lipopolysaccharide-induced neuroinflammation in vitro and in vivo. [Abstract]

2020 Jan;41(1):10-21. PMID: 31213669
Free Radic Biol Med

Screening of NSAIDs library identifies Tinoridine as a novel ferroptosis inhibitor for potential intervertebral disc degeneration therapy. [Abstract]

2024 May 26:221:245-256. PMID: 38806104
Oncogene

Upconversion mesoporous silica nanoparticles co-delivering celecoxib and rose bengal enable multimodal immunogenic and anti-angiogenic therapy for spinal metastasis of non-small cell lung cancer. [Abstract]

2026 Mar;45(9):823-839. PMID: 41673094
Cell Rep

Notch-mediated lactate metabolism regulates MDSC development through the Hes1/MCT2/c-Jun axis. [Abstract]

2022 Mar 8;38(10):110451. PMID: 35263597
Br J Cancer

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. [Abstract]

2018 Jan;118(2):213-223. PMID: 29123257

Celecoxib purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2018 Jan;118(2):213-223. [Abstract]

Western blotting of EP2, EP4, COX-2, and PTEN using proteins extracted from SVHUC cells without MCA exposure and MCA-exposed SVHUC cells subsequently cultured for 6 weeks with ethanol or Celecoxib (1 mM). GAPDH served as a loading control.
Mol Med

COX-2 inhibition as a therapeutic strategy for bone loss in Staphylococcus aureus osteomyelitis. [Abstract]

2025 May 7;31(1):177. PMID: 40335904
Front Immunol

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy. [Abstract]

2021 May 26:12:670088. PMID: 34122428
Biochem Pharmacol

ALA-PDT Augments Intense Inflammation in the Treatment of Acne Vulgaris by COX2/TREM1 Mediated M1 Macrophage Polarization. [Abstract]

2023 Feb:208:115403. PMID: 36592708
J Ethnopharmacol

Soufeng Sanjie formula and its active ingredient formononetin alleviate osteoarthritis via PPARG-AKT-ERK1/2 promoted cartilage extracellular matrix anabolism. [Abstract]

2026 May 10:362:121320. PMID: 41633494
Cancer Immunol Immunother

VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function. [Abstract]

2025 Jul 30;74(9):278. PMID: 40736709
Life Sci

Oxalate stimulates macrophage secretion of prostaglandin E2 to promote renal tubular epithelial cell osteogenesis. [Abstract]

2025 Apr 1:366-367:123476. PMID: 39986650
Life Sci

PTGS2: A potential immune regulator and therapeutic target for chronic spontaneous urticaria. [Abstract]

2024 May 1:344:122582. PMID: 38514006
Int J Mol Sci

Naringin Alleviates Knee Osteoarthritis by Targeting TNF-α and PTGS2: An Integrated Network Pharmacology, Molecular Simulation, and Experimental Validation Study. [Abstract]

2026 Feb 13;27(4):1812. PMID: 41751946
Cell Mol Neurobiol

Neuroprotective Effects of the Nonsteroidal Anti-inflammatory Drug Celecoxib Against Caspase-1-dependent Pyroptosis Partially by Suppressing the HMGB1/TLR4 Pathway. [Abstract]

2025 Oct 23;45(1):91. PMID: 41129001
Int Immunopharmacol

Microbial metabolite tigloside alleviates osteoarthritis by repolarizing macrophages from M1 to M2 phenotype through Trafd1 destabilization and Trafd1-mediated NF-κB/STAT6 signaling pathways. [Abstract]

2026 Jan 1;168(Pt 1):115747. PMID: 41192114
Eur J Pharmacol

Restoration of ARA metabolic disorders in vascular smooth muscle cells alleviates intimal hyperplasia. [Abstract]

2024 Sep 10:176824. PMID: 39265882
Int Immunopharmacol

Effect of radiation fractionation on IDO1 via the NF-κB/COX2 axis in non-small cell lung cancer. [Abstract]

2023 Sep 24;124(Pt B):110956. PMID: 37751656
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Front Microbiol

Cyclooxygenase-2 Facilitates Newcastle Disease Virus Proliferation and Is as a Target for Canthin-6-One Antiviral Activity. [Abstract]

2020 May 20;11:987. PMID: 32508794
Cancers (Basel)

Crosstalk Between nNOS/NO and COX-2 Enhances Interferon-Gamma-Stimulated Melanoma Progression. [Abstract]

2025 Jan 31;17(3):477. PMID: 39941844
Cancers

Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism. [Abstract]

2019 Jul 3;11(7):931. PMID: 31277230
J Cell Mol Med

Aspirin Attenuates Liver Fibrosis via Autophagy Induction. [Abstract]

2025 Jul;29(13):e70696. PMID: 40611443
iScience

Activated platelets facilitate hematogenous metastasis of breast cancer by modulating the PDGFR-β/COX-2 axis. [Abstract]

2023 Aug 23;26(9):107704. PMID: 37680480
JOR Spine

M1 macrophage-derived oncostatin M induces osteogenic differentiation of ligamentum flavum cells through the JAK2/STAT3 pathway. [Abstract]

2023 Oct 18;7(1):e1290. PMID: 38222812
J Cell Commun Signal

Modulation of aryl hydrocarbon receptor inhibits esophageal squamous cell carcinoma progression by repressing COX2/PGE2/STAT3 axis. [Abstract]

2020 Jun;14(2):175-192. PMID: 31925646
J Biol Chem

Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) mediate cell density-dependent proinflammatory responses. [Abstract]

2018 Nov 23;293(47):18071-18085. PMID: 30315101
Oncol Rep

Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer. [Abstract]

2018 Oct;40(4):2242-2250. PMID: 30066906

Celecoxib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Oct;40(4):2242-2250. [Abstract]

Effects of Gefitinib(G) and Celecoxib(Cel) on ABCB1 (MDR1), FOXM1 and Bcl 2 protein levels in PC3/DR and DU145/DR cell lines. The effects of Gefitinib, Celecoxib and their combination on ABCB1 (MDR1), FOXM1 and Bcl 2 expression in the PC3/DR and DU145/DR cell lines are determined by a western blot assay.
Sci Rep

Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. [Abstract]

2018 Mar 7;8(1):4108. PMID: 29515134

Celecoxib purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Mar 7;8(1):4108. [Abstract]

L02 cells exposed to PA (200 μM) with different concentrations of Celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreases protein expression of COX-2 compared with control as indicated by western blot.
J Pharmacol Exp Ther

Thymidine Kinase 1 Mediates the Synergistic Antitumor Activity of Ubenimex and Celecoxib via Regulation of Cell Cycle in Colorectal Cancer. [Abstract]

2022 Aug;382(2):188-198. PMID: 35868865
Clin Exp Med

Decoding intratumoral cyclooxygenase-2 signaling through multi-omics: insights from esophageal cancer and beyond. [Abstract]

2025 Nov 18;26(1):8. PMID: 41249574
Exp Cell Res

Selenomethionine protects oxidative-stress-damaged bone-marrow-derived mesenchymal stem cells via an antioxidant effect and the PTEN/PI3K/AKT pathway. [Abstract]

2021 Nov 15;408(2):112864. PMID: 34626586
Cancer Res Commun

Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors. [Abstract]

2023 Aug 8;3(8):1486-1500. PMID: 37559947
Front Oncol

Pyruvate Kinase M2 Promotes Prostate Cancer Metastasis Through Regulating ERK1/2-COX-2 Signaling. [Abstract]

2020 Sep 29:10:544288. PMID: 33117682
Pathol Res Pract

Targeting CDH11 with celecoxib and derivatives to suppress esophageal squamous cell carcinoma proliferation and invasion. [Abstract]

2025 May 27:272:156042. PMID: 40460640
Cell Transplant

Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma. [Abstract]

2022 Jan-Dec:31:9636897221077921. PMID: 35176901
Naunyn Schmiedebergs Arch Pharmacol

Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages. [Abstract]

2025 May 31. PMID: 40448826
Naunyn Schmiedebergs Arch Pharmacol

Study on the mechanism of puerarin against osteoarthritis from ferroptosis based on network pharmacology and bioinformatics. [Abstract]

2024 Feb;397(2):959-968. PMID: 37548663
Peptides

Endogenous ET-1 promotes ANP secretion through activation of COX2-L-PGDS-PPARγ signaling in hypoxic beating rat atria. [Abstract]

2019 Dec;122:170150. PMID: 31541683
Oncotargets Ther

Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 Expression in Lung Adenocarcinoma. [Abstract]

2020 Aug 18;13:8197-8208. PMID: 32904445
J Nat Med

Diosmetin alleviates osteoarthritis through modulating the polarization of macrophages by inhibiting the PI3K/Akt signaling pathway. [Abstract]

2025 Sep;79(5):1030-1043. PMID: 40702221
Hereditas

Corynoxine suppresses lung adenocarcinoma proliferation and metastasis via inhibiting PI3K/AKT pathway and suppressing Cyclooxygenase-2 expression. [Abstract]

2024 Nov 7;161(1):41. PMID: 39511658
Clin Exp Pharmacol Physiol

Ellagic acid improves osteoarthritis by inhibiting PGE2 production in M1 macrophages via targeting PTGS2. [Abstract]

2024 Oct;51(10):e13918. PMID: 39188023
Head Neck

iPLA2β regulates the dual effects of arachidonic acid in thyroid cancer. [Abstract]

2025 Feb;47(2):504-516. PMID: 39290130
Am J Transl Res

Cyclooxygenase-2 expressed hepatocellular carcinoma induces cytotoxic T lymphocytes exhaustion through M2 macrophage polarization. [Abstract]

2021 May 15;13(5):4360-4375. PMID: 34150019
Res Sq

2026 Jun 4.
University of Kansas

2025.
Res Sq

2024 Sep 05.
Patent

US20220339168A1.
Oxid Med Cell Longev

Cepharanthine Attenuates Early Brain Injury after Subarachnoid Hemorrhage in Mice via Inhibiting 15-Lipoxygenase-1-Mediated Microglia and Endothelial Cell Ferroptosis. [Abstract]

2022 Feb 9;2022:4295208. PMID: 35186185

Solvente y solubilidad

In Vitro:

DMSO : ≥ 50 mg/mL (131.11 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6221 mL

13.1106 mL

26.2213 mL

5 mM

0.5244 mL

2.6221 mL

5.2443 mL

10 mM

0.2622 mL

1.3111 mL

2.6221 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[2]

The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 h. The cells are then treated with increasing concentrations of Celecoxib (0, 5, 10, 25, 50 or 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 h. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37°C for 4 h. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The percentage growth inhibition is calculated as (OD_control−OD_drug)/OD_control×100%. The half-maximal inhibitory concentration (IC₅₀) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]^[4]

Mice^[3]
The KpB mice are monitored weekly by palpation for tumor growth. Celecoxib and placebo treatment is initiated after palpation of a 1 cm tumor in mice on the HFD (obese group) and LFD (non-obese group) (N=15 mice per group). Celecoxib is dissolved in DMSO at 5 mg/mL, further diluted 10 times in 0.5% methylcellulose with 0.025% Tween 80 and injected (IP) daily at a dose of 5 mg/kg body weight for 4 weeks. The tumor sizes are measured once a week by palpation. Tumor volume is calculated using the following equation: volume (mm³)=a×b²/2, where is the largest diameter and b is the smallest diameter. The animals are weighed weekly throughout the study. At sacrifice, mice are weighed and blood samples are taken. Half of the ovarian tumor is snap-frozen and stored at −80°C, and the other half is fixed in 10% neutral-buffered formalin and paraffin embedded. Mouse heart, lungs and kidneys are also harvested, fixed in formalin and grossly examined for any suspicious lesions before paraffin embedding.
Rats^[4]
Forty adult, clean, female, Sprague-Dawley rats aged 3 months and weighing 280-330 g, are used. Forty rats are randomized to five groups as follows: sham surgery, model, Celecoxib, fasudil and combination groups, with eight rats in each group. Rats in the Celecoxib group are intragastrically administrated with a suspension of Celecoxib (20 mg/kg), and a suspension of Celecoxib containing 0.5% sodium carboxymethylcellulose is made from the capsules. Rats in the fasudil group are intramuscularly administrated with fasudil hydrochloride injection (10 mg/kg) via the dorsal muscle. Rats in the combination group are administrated with both a suspension of Celecoxib (20 mg/kg) and fasudil hydrochloride (10 mg/kg). The fasudil and Celecoxib doses are based on doses administered to adults and these are adjusted in a pre-study. Administration is once every day for 2 weeks. Subsequently, all rats are treated normally for another 2 weeks, and then sacrificed either for histological examination or for western blot assay.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (285 KB)
SDS (623 KB)
- English - EN (623 KB)
- Français - FR (623 KB)
- Deutsch - DE (623 KB)
- Norwegian - NO (623 KB)
- Español - ES (623 KB)
- Swedish - SV (623 KB)
- Italian - IT (623 KB)
- Korean - KR (623 KB)
- Portuguese - PT (623 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997 [Content Brief]

[2]. Liu DB, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin. 2012 May;33(5):682-90. [Content Brief]

[3]. Suri A, et al. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. Oncotarget. 2016 Apr 8. [Content Brief]

[4]. Hou XL, et al. Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone. Neural Regen Res. 2015 Nov;10(11):1836-40. [Content Brief]

[5]. Liu C, et al. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. Sci Rep. 2018 Mar 7;8(1):4108. [Content Brief]

[6]. Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6221 mL	13.1106 mL	26.2213 mL	65.5531 mL
	5 mM	0.5244 mL	2.6221 mL	5.2443 mL	13.1106 mL
	10 mM	0.2622 mL	1.3111 mL	2.6221 mL	6.5553 mL
	15 mM	0.1748 mL	0.8740 mL	1.7481 mL	4.3702 mL
	20 mM	0.1311 mL	0.6555 mL	1.3111 mL	3.2777 mL
	25 mM	0.1049 mL	0.5244 mL	1.0489 mL	2.6221 mL
	30 mM	0.0874 mL	0.4370 mL	0.8740 mL	2.1851 mL
	40 mM	0.0656 mL	0.3278 mL	0.6555 mL	1.6388 mL
	50 mM	0.0524 mL	0.2622 mL	0.5244 mL	1.3111 mL
	60 mM	0.0437 mL	0.2185 mL	0.4370 mL	1.0926 mL
	80 mM	0.0328 mL	0.1639 mL	0.3278 mL	0.8194 mL
	100 mM	0.0262 mL	0.1311 mL	0.2622 mL	0.6555 mL

Keywords

Celecoxib

64 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Celecoxib

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

Antidepressant Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Anti-Aging Natural Product Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Celecoxib

Ver todos los productos específicos de isoformas COX

Actividad biológica

Chemical Information

Publications (64)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Celecoxib Related Classifications

HY-14398 Related Classifications